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Equine Protozoal Myeloencephalitis: An Updated Consensus
Statement with a Focus on Parasite Biology, Diagnosis, Treatment,
and Prevention
S.M. Reed, M. Furr, D.K. Howe, A.L. Johnson, R.J. MacKay, J.K. Morrow, N. Pusterla, and
S. Witonsky
Equine protozoal myeloencephalitis (EPM) remains an important neurologic disease of horses. There are no pathog-
nomonic clinical signs for the disease. Affected horses can have focal or multifocal central nervous system (CNS) disease.
EPM can be difficult to diagnose antemortem. It is caused by either of 2 parasites, Sarcocystis neurona and Neospora hughesi,
with much less known about N. hughesi. Although risk factors such as transport stress and breed and age correlations have
been identified, biologic factors such as genetic predispositions of individual animals, and parasite-specific factors such as
strain differences in virulence, remain largely undetermined. This consensus statement update presents current published
knowledge of the parasite biology, host immune response, disease pathogenesis, epidemiology, and risk factors. Importantly,
the statement provides recommendations for EPM diagnosis, treatment, and prevention.
Key words: Encephalitis; Equine myeloencephalopathy; Equine neurologic; Equine protozoal disease; Myelitis; Neospora
hughesi; Sarcocystis neurona.
Parasite Biology and Disease Pathogenesis
EPM was initially called “segmental myelitis” byRooney in Kentucky in 1970.1 The syndrome was
renamed “focal encephalitis-myelitis” because of brain
involvement. Prickett, Rooney, and others described 44
cases of the disease in 19682 and 52 cases of the disease
in 19701 at the annual meeting of the American Associ-
ation of Equine Practitioners (AAEP). Protozoa were
first observed in association with characteristic lesions
in 1974,3,4 and the disease was given its current name,
equine protozoal myeloencephalitis by Mayhew et al.,
who reported on 45 cases at the AAEP meeting in
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1976.5 It is now well established that EPM can be
caused by either Sarcocystis neurona6 or Neospora hugh-
esi,7–11 although the majority of cases are because of
infection with S. neurona.
Sarcocystis neurona has a 2-host life cycle that alter-
nates between the definitive host, and any of multiple
mammal intermediate hosts. The opossum Didelphis vir-
giniana is the definitive host for S. neurona in North
America.12 As well, South American opossums can act
as definitive hosts for S. neurona in the southern hemi-
sphere.13 Sexual reproduction by the parasite in the
intestinal epithelium of the infected opossum results in
the production of sporozoite-containing sporocysts that
are passed in the feces. The sporozoites are infectious
for the intermediate hosts, which include skunks,14 rac-
coons,15 armadillos,16 and cats.17 S. neurona forms
latent sarcocysts in the muscle tissue of the intermediate
host; sarcocyst-laden muscle is the source of infection
for the opossum. Opossums are commonly infected
with S. neurona18 and can generate significant contami-
nation of the environment in locations which they fre-
quent.
Horses are infected with S. neurona by ingesting food
or water that has been contaminated with feces from an
infected opossum. Although S. neurona sarcocysts were
described in 1 case of a 4-month-old foal with clinical
signs of EPM,19 it is unlikely that horses are normal
intermediate hosts that contribute to the parasite’s life
cycle as S. neurona sarcocysts are not found typically in
tissues of these animals and equine carcasses are seldom
accessible to opossums. Importantly, S. neurona is not
transmitted horizontally between horses, nor can it be
transmitted to horses from nonequine intermediate
hosts. Antibodies against S. neurona in foals before
suckling have been reported,20,21 but vertical transmis-
sion of this parasite in horses is probably uncommon.
Thus, opossums are the major source of S. neurona
infection for horses. The exact mechanisms by which
S. neurona enters the CNS are not known, but are
thought to involve either infection of endothelial cells
or leukocytes.22–25
The complete life cycle of N. hughesi is unknown, so
all mode(s) of transmission of this parasite to horses
remain poorly understood. Canids are a definitive host
for the related species Neospora caninum,26 but it has
not been established that dogs or wild canids are a
definitive host for N. hughesi. Vertical transmission of
N. caninum is very efficient in cattle, and several recent
studies indicate that N. hughesi can be transmitted
transplacentally in horses.27,28
All horses are believed to be susceptible to EPM, but
it is clear that not all horses that are infected with
S. neurona or N. hughesi will develop disease. Studies in
both mice and horses experimentally infected with
S. neurona have demonstrated a critical role for the
immune response in preventing disease.29–32 Addition-
ally, some EPM-affected horses have demonstrated
altered immune responses, some of which are antigen-
specific.25,33–35 As is clear from the finding that not all
horses have demonstrated decreased immune responses
with the methodology employed, the mechanisms
involving the development of disease remain poorly
understood.
It is unclear what influences the progression to severe
neurologic disease. Factors such as variations in proto-
zoal inoculum and stress-induced immune suppression
have been implicated in the occurrence of EPM.36–38
However, efforts to increase stress (ie, by additional
transport of infected horses) and treatment with
immunosuppressive steroids did not cause a concomi-
tant increase in disease severity.39,40 Genetic variation
has been observed among the strains of S. neurona that
have been analyzed,41–43 and there is some evidence that
specific parasite genotypes may be particularly virulent
in marine mammals.44 However, such an association
was not apparent in isolates from horses suffering from
EPM.
Epidemiology and Risk Factors
A survey using postmortem data from 10 diagnostic
centers throughout the United States and Canada found
that a majority of EPM cases (61.8%) occurred in horses
that were 4 years old or less, whereas only 19.8% of the
EPM cases reviewed were in horses 8 years or older.45
Thoroughbreds, Standardbreds, and Quarter Horses
were most commonly observed, but no sex or seasonal
bias could be established. A smaller retrospective study
of 82 horses with histologic lesions compatible with EPM
suggested that EPM risk was highest among male Stan-
dardbreds.46 The mean age of affected horses was 3.6 
2.8 years, similar to that found by Fayer et al.45
The seroprevalence of S. neurona in horses from the
United States has varied widely, ranging from as low as
15% to a high of 89%, depending on geographic loca-
tion.47–51 Seroprevalences of 35.6% and 35.5% have
been observed in horses in Brazil and Argentina, respec-
tively,52,53 thus indicating that this parasite commonly
infects horses in South America.
In general, the seroprevalence of N. hughesi is low in
horses. Serum antibodies against N. hughesi have been
reported in more than 10% of horses in some geo-
graphic regions,7,54–58 whereas other studies found anti-
bodies against N. hughesi in much lower proportions of
horses (ie, <3%).52,53,59–62 Some of the variation may be
because of geographic differences, but studies that used
Western blot to confirm serologic results have suggested
that seroprevalence to N. hughesi is commonly overesti-
mated.57,59,62
A survey reported in 2001 by the National Animal
Health Monitoring System (NAHMS) estimated that
the annual incidence of EPM in horses 6 months of age
or older was 14  6 cases per 10,000 horses.63 While it
is now known that N. hughesi can cause neurologic dis-
ease in horses,7–11 the proportion of EPM cases attribu-
table to this parasite species remains uncertain.
EPM usually occurs sporadically and seldom involves
more than 1 horse on a farm,5,64 although clusters of
cases can occur.65,66 A retrospective study found that
young horses (1–5 years) and older horses (>13 years)
had a higher risk of developing EPM,67 as observed
previously. EPM occurred the least in the winter, with
492 Reed et al
the risk 3 times higher in spring and summer and 6
times higher in the fall. On a given premise, the pres-
ence of opossums (2.5-fold), previous diagnosis of EPM
(2.5-fold), and the presence of wooded areas (2-fold)
were also associated with increased risk of EPM. The
likelihood of EPM was reduced by one third when wild-
life was prevented access to feed and by one-half when
a creek or river was present as a water source.
Immune suppression because of stress or advanced age
might predispose a horse to development of EPM.36
Stressful events such as heavy exercise, transport, injury,
surgery, or parturition have all been found to increase
the risk of EPM.67 Racehorses and show horses had a
higher risk of developing EPM compared to breeding
and pleasure horses. Not surprisingly, horses with EPM
that were treated with an anticoccidial drug were 10 times
more likely to improve than untreated horses.36
Clinical Signs
Clinical signs of EPM vary from acute to chronic
with insidious onset of focal or multifocal signs of neu-
rologic disease involving the brain, brainstem, or spinal
cord.64 Initial signs might include dysphagia, evidence
of abnormal upper airway function, unusual or atypical
lameness, or even seizures.68 Severely affected horses
might have difficulty standing, walking, or swallowing
and the disease can progress very rapidly. Occasionally,
the clinical signs stabilize, only to relapse days or weeks
later.
The variability of clinical signs is because of infection
of both white and gray matter at multiple sites in the
CNS. Signs of gray matter involvement include focal
muscle atrophy and severe muscle weakness, whereas
damage to white matter frequently results in ataxia and
weakness in limbs caudal to the site of infection. Early
signs of EPM such as stumbling and frequent interfer-
ence between limbs can be confused with lameness.
Horses affected with EPM commonly exhibit a gradual
progression in severity and range of clinical signs. In
some cases, however, a gradual onset can give way to a
sudden exacerbation in the severity of clinical illness,
resulting in recumbency.
The vital signs in affected horses are usually normal
and animals appear bright and alert. Some horses with
EPM appear thin and mildly obtunded. Neurologic
examination often reveals asymmetric ataxia, weakness,
and spasticity involving all 4 limbs. Areas of hyporeflex-
ia, hypalgesia, or complete sensory loss are occasionally
present. The most common signs of brain/brainstem
disease include obtundation, head tilt, facial nerve
paralysis, and difficulty in swallowing, although signs
are not necessarily limited to these areas.69
Recommendations for EPM Diagnosis
Definitive diagnosis of EPM requires postmortem con-
firmation of protozoal infection of the CNS (see below).
For highest accuracy in antemortem diagnosis, the fol-
lowing steps are recommended. (1) The presence of clini-
cal signs consistent with EPM should be confirmed by
conducting a thorough neurologic examination. (2) Other
potential causes should be ruled out using available tools
(eg, cervical radiography). (3) Immunodiagnostic testing
of serum and CSF should be conducted to confirm
intrathecal antibody production against S. neurona or
N. hughesi. The ratio of antibody in serum to CSF will
reveal intrathecal antibodies in most cases of EPM. The
Goldman-Witmer coefficient (C-value) or the antigen-
specific antibody index (AI) should be applied for cases
that have ELISA titer results that are equivocal (ie, the
serum:CSF ratio equals the cut-off) or when a condition
that compromises the blood–brain barrier is suspected.
The SnSAG2, 4/3 ELISA serum:CSF titer ratio and
NhSAG1 ELISA serum:CSF titer ratio are the only tests
currently offered commercially that provide information
regarding intrathecal antibody production based on
serum and CSF titers. The commercially available S. neu-
rona and N. hughesi IFATs do determine antibody titers
in both the serum and CSF, but the laboratory does not
calculate ratios at this time.
Basis for Recommendations
In horses with clinical signs consistent with CNS dis-
ease, EPM should be considered as a differential.
Affected horses should initially have a thorough neuro-
logic examination to identify abnormalities, and localize
the lesion(s), which will allow one to further refine the
differentials. This, combined with the use of appropriate
diagnostic tests, will assist in diagnosing EPM and rul-
ing out other causes. Some of the most consistent/clas-
sic clinical signs include asymmetric gait and focal
muscle atrophy. When these signs are present, EPM
should be considered as a top differential diagnosis.
EPM-affected horses are not painful, and rarely febrile,
unless comorbidities exist.
Differential Diagnoses
Almost all neurologic diseases in horses can have
clinical signs that are also present in EPM-affected
horses. A thorough neurologic examination and diag-
nostic tests are needed to distinguish between EPM and
other differentials. Some diseases have other more con-
sistent/classic signs that allow one to rule them in or
out. With cervical vertebral stenotic myelopathy
(CVSM), signs usually are symmetric and, typically, the
pelvic limbs are more severely affected than the thoracic
limbs. Focal muscle atrophy is not common. Trauma
should also be considered as a differential cause of
spinal cord damage at any level, potentially causing
abnormal neurologic signs in 1 to all limbs.
In horses where there is a history of respiratory dis-
ease or an outbreak of abortion, EHV-1-associated neu-
rologic disease should be considered as a more likely
differential. EHV-1-affected horses may be febrile
shortly before or at the onset of neurologic signs. In the
EHV-1-affected horses, neurologic signs typically mani-
fest as symmetric, with primary pelvic limb weakness
and ataxia, bladder distention, usually without inconti-
nence, and, more rarely, perineal hypalgesia, tail paraly-
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sis, fecal retention and in some cases incontinence as
well. Some affected horses show rapidly progressing
signs of ataxia and can sometimes have cranial nerve
deficits, often involving cranial nerves VII to XII. In
other cases, cerebral signs occur.
Another disease which should be considered as a dif-
ferential diagnosis is equine motor neuron disease
(EMND). Affected horses with early stages of disease
typically have severe limb weakness with muscle fascicu-
lations and tremors. Horses with chronic EMND can
have widespread, profound, muscle atrophy.
Other differentials of spinal cord disease that can result
in similar clinical signs include extradural and spinal cord
tumors, epidural abscess, migrating metazoan parasites,
rabies, West Nile viral encephalomyelitis, equine degener-
ative myeloencephalopathy/neuroaxonal dystrophy, lead
poisoning, creeping indigo toxicity, Lyme neuro-borrelio-
sis, vascular malformations, and discospondylopathies. If
affected horses have signs of cranial nerve or brain
involvement, EPM should be considered as a differential.
Other rule outs include viral encephalomyelitides, neo-
plasia, head trauma, brain abscess, migrating parasites,
temporohyoid osteoarthropathy, polyneuritis equi,
cholesterol granuloma, metabolic derangement, and hep-
atoencephalopathy.
Postmortem Diagnosis
Confirmation of EPM on postmortem examination is
based on demonstration of protozoa in CNS lesions,
although the diagnosis frequently is made presumptively
even when parasites are not detected if the characteristic
inflammatory changes are found. In 2 reported series,
organisms were seen in H&E sections of CNS tissue in
10 to 36% of suspected cases.46,70 Sensitivity was
increased from 20 to 51% by immunohistochemical
staining with antibody against S. neurona.70 Although it
has not been demonstrated experimentally, the use of
PCR to detect parasites in CNS tissues might aid post-
mortem diagnosis of EPM. There is decreased likeli-
hood of finding parasites histologically in tissues from
affected EPM horses that have been treated with
antiprotozoal drugs.46
Immunodiagnostic Testing
Overview
There are several immunodiagnostic tests currently in
use for EPM diagnosis. Importantly, these tests are an
adjunct to diagnosis and not the mainstay. Performing
serology as part of a general health screen or prepur-
chase examination is discouraged because of the very
low positive predictive value when a nonneurologic
horse is tested. In horses showing gait deficits, EPM
serology should not be used to distinguish whether the
deficits are caused by CNS or musculoskeletal disease.
Presence or absence of neurologic disease is determined
by the clinical examination, and serology can then help
refine the differential diagnoses list for a neurologic
horse.
All commonly used tests are based on detection of
antiprotozoal antibodies in serum, CSF, or both. As
EPM occurs only in a small proportion of horses
infected with S. neurona,63 testing for serum antibodies
against S. neurona has minimal diagnostic value unless
the serologic results are negative (low positive predictive
value but high negative predictive value).71,72 However,
detection of serum antibodies against N. hughesi in a
neurologic horse has a higher positive predictive value
because of a much lower seroprevalence. A negative
serum test usually indicates that the horse has not been
infected and alternative diagnoses should be pursued or
that the EPM-suspect horse resides in a geographic area
of low exposure to the infecting parasite. However, a
recently infected horse might display clinical signs
before seroconversion, and repeated serologic testing in
10–14 days is indicated for horses with recent develop-
ment of compatible clinical signs. Detection of antibod-
ies in the CSF is more informative, but alone is not a
definitive indicator of EPM as there is passive transfer
of antibody across a healthy blood–brain barrier
(BBB).73 Additionally, blood contamination of CSF
samples can cause false-positive results.74–76 Logically,
horses with higher serum titers are more likely to have
detectable antibody levels in CSF in both of these cir-
cumstances.
Use of quantitative assays to detect intrathecal anti-
body production, indicating active parasite infection in
the CNS, provides an accurate approach for EPM diag-
nosis. The Goldman-Witmer coefficient (C-value) and the
antigen-specific antibody index (AI) are tests of propor-
tionality that assess whether the amount of pathogen-spe-
cific antibody in the CSF is greater than should be
present from normal passive transfer across the BBB.
These methods have been used in human medicine to
diagnose CNS infections caused by a variety of
pathogens,77–79 including the apicomplexan T. gondii.80,81
The value of these tests for EPM diagnosis was demon-
strated initially with a sample set of 29 clinical cases.75
This study also showed that minor blood contamination
of the CSF sample (ie, up to 10,000 red cells per lL) will
not confound the assay results. Subsequently, 2 addi-
tional studies examining a more extensive collection of
horses with neurologic disease showed that a simple
serum:CSF antibody titer ratio was sufficient in many
cases for an accurate diagnosis of EPM caused by S. neu-
rona.71,72 Although use of a serum:CSF titer ratio should
be equally effective for diagnosis of EPM caused by
N. hughesi, an optimal serum:CSF titer ratio cut-off
needs to be established.
Available tests for EPM caused by S. neurona
Numerous serologic tests have become available dur-
ing the past 2 decades to aid in the diagnosis of EPM
caused by S. neurona, including Western blot (WB),
indirect fluorescent antibody test (IFAT), and surface
antigen (SAG) enzyme-linked immunosorbent assays
(ELISAs). Descriptions of testing options and reported
test performance are shown in Table 1.71,72,82–93 All
tests can be performed on serum or CSF, and none is
494 Reed et al
considered a gold standard. The WB, the first immun-
odiagnostic test described for EPM, is a qualitative test
for antibodies against merozoite lysate. Its use has lar-
gely been supplanted by more quantitative tests, and
positive WB results have limited diagnostic utility.
However, negative WB results retain a high negative
predictive value. The IFAT is a quantitative (end-point
titer) test for antibodies against culture-derived whole
merozoites. Although serum titers obtained with the
IFAT have been used to predict the likelihood of EPM,
with higher titers suggesting greater probability of dis-
ease, studies that have used diverse collections of neuro-
logic disease cases have shown that a serum titer alone
is a poor predictor of EPM.71,72 As a quantitative test,
the IFAT can be used to calculate a serum:CSF titer
ratio. However, this information is not routinely pro-
vided by the laboratory.
Most recent research has focused on the SAG ELI-
SAs, quantitative (end-point titer) tests based on S. neu-
rona surface antigens. These molecules have proven to
be good serologic targets in the assays because of their
high level of expression in the parasite and their
immunogenicity in infected horses.94–96 The SnSAG2
ELISA and the SnSAG4/3 ELISA accurately detect
antibodies against S. neurona in equine serum and CSF
samples88,91 and were used to demonstrate the value of
detecting intrathecal antibody production for EPM
diagnosis.71,72 An ELISA based on the SnSAG1 surface
protein has been described.86 However, this antigen is
not expressed by all strains of S. neurona,43 thereby
reducing its utility for serologic detection88 and EPM
diagnosis.89 An ELISA combining SnSAG1 with 2
additional SnSAGs (SnSAG5 and SnSAG6) is currently
offered. However, no published reports describe valida-
tion of this assay, so it is unclear whether the test reli-
ably detects antibodies to S. neurona.
Several studies have directly compared different tests
for EPM (caused by S. neurona infection);71,83,89 these
publications and 3 unpublished studies presented at
ACVIM EPM Society SIGs97–99 are detailed in
Table 2.71,83,89,97–99 Although none of the studies exam-
ined all of the currently available tests, and the types of
samples utilized were variable, some general conclusions
are evident. Testing serum alone yielded less accurate
results than testing CSF alone or a serum:CSF titer
ratio, generally because of low specificity. One notable
exception was the SAG1 ELISA, which showed poor
sensitivity. Poor to fair test agreement was observed;
samples that were split and submitted to multiple labs
often had discrepant results. Three of the 6 comparison
studies evaluated the SAG2, 4/3 ELISA serum:CSF titer
ratio; in all 3 studies this test demonstrated the highest
Table 1. Performance of commercially available immunologic tests for antibodies against Sarcocystis neurona.
Test Laboratory Interpretation
Reported performance
Sample Sensitivity (%) Specificity (%)
WB87 EDS Band pattern read and
interpreted visually (subjective)
Serum 8993, 8082, 8983 7193, 3882, 8783
UC Davis
IDEXX
Results usually reported
as negative, weak positive,
low positive, or positive
CSF 8993, 8782 8993, 4482
mWB90 Michigan
State
Similar to standard WB (above) Serum 10090, 8983 9890a, 6983 (an.b., negative
cases not from
North America)
IFAT83 UC Davis Serum positive at ≥1:80
has ≥55% probabilitya of EPM
Serum 8983, 8384, 9489, 5971 10083, 9784, 8589, 7171
Serum negative at ≤1:40
has ≤33% probabilitya of EPM
CSF 10084, 9289, 6571 9984, 9089, 9871
CSF positive at ≥1:5
has 92% probabilitya of EPM
Serum:CSF
titer ratio
6571 9871
SAG1 ELISA86 Antech Serum positive at ≥1:16
but recommended cutoff ≥1:32
Serum 6888, 1389 7188, 9789
SAG2, 4/3
ELISA91
EDS Serum positive for
exposure at ≥1:250
Serum 30–86
(depending
on cutoff)72, 7171
37–88 (depending
on cutoff)72, 5071
CSF correlates well with
EPM if ≥1:40
CSF 77–96
(depending
on cutoff)72, 8871
58–96 (depending
on cutoff)72, 8671
Serum:CSF titer ratio very
predictive of EPM if ≤100
Serum:CSF
titer ratio
86 (cutoff ≤50)
or 93
(cutoff ≤100)72, 8871
96 (cutoff ≤50) or 83
(cutoff ≤100)72, 10071
SAG1, 5, 6
ELISA92
Pathogenes Serum positive at ≥1:8,
indicating infection
Serum N/A N/A
WB, Western blot; mWB, modified Western blot; IFAT, indirect fluorescent antibody test; SAG, surface antigen; ELISA, enzyme-linked
immunosorbent assay; EDS, Equine Diagnostic Solutions (Lexington, KY); UC Davis, University of California at Davis; EPM, equine
protozoal myeloencephalitis; CSF, cerebrospinal fluid.
aBased on pretest probability of 10%; see reference 85.
EPM: An Updated Consensus Statement 495
overall accuracy as compared to the WB, IFAT, and
SAG1 ELISA. However, the SAG1, 5, 6 ELISA has
not yet been evaluated in any comparison study, so its
performance is currently unknown.
Available tests for EPM caused by N. hughesi
Two serologic assays are currently offered for mea-
suring antibodies against N. hughesi in equine samples
Table 2. Test comparisons related to EPM caused by Sarcocystis neurona
References
Tests (and samples)
compared Sample origin Results Author conclusions
Duarte
et al. (2003)83
 WB (serum)
 mWB (serum)
 IFAT (serum)
 Necropsy cases
(9 positive, 39 negative)
 Similar Se (89%) for all 3
 Variable Sp
(IFAT 100%,
WB 87%, mWB 69%)
IFAT accuracy was
better than
WB tests.
Saville (2007)99  WB (serum)
 mWB (serum)
 IFAT (serum)
 SAG1 ELISA
(serum)
 Experimental cases
(1 Sarcocystis neurona
positive,
1 S. fayeri positive,
2 negative)
 Clinical cases
(3 positive, 10 negative)
 Necropsy case
(1 positive)
 Variable for each case;
limited agreement
between tests
WB and IFAT
were most
accurate, though
IFAT was
cross-reactive with
S. fayeri. mWB
tended to have
false-positive
results, whereas
SAG1 ELISA
tended to have
false-negative
results.
Johnson
et al. (2010)89
 IFAT
(serum, CSF)
 SAG1 ELISA
(serum)
 Necropsy cases
(9 positive, 17
negative)
 Clinical cases
(10 positive, 29
negative)
 Marked difference in Se
(IFAT serum 94%, IFAT
CSF 92%, SAG1
ELISA serum 13%)
 Comparable Sp
(IFAT serum 85%, IFAT
CSF 90%, SAG1 ELISA
serum 97%)
Low Se limited the
usefulness of the
SAG1 ELISA.
Reed
et al. (2010)97
 WB (CSF)
 IFAT (serum)
 SAG1 ELISA
(serum)
 SAG2, 4/3 ELISA
(serum:CSF ratio)
 Necropsy cases
(7 positive, 5 negative)
 Clinical cases
(6 positive, 2 negative)
 Variable Se (SAG2, 4/3
ELISA 90%, WB 90%,
IFAT 70%, SAG1
ELISA 55%)
 Variable Sp (SAG2, 4/3
ELISA 100%, WB 95%,
SAG1 ELISA 90%,
IFAT 85%)
SAG2, 4/3 ELISA
serum:CSF ratio
was the most
accurate.
Renier
et al. (2012)98
 IFAT (CSF)
 SAG2, 4/3 ELISA
(serum:CSF ratio)
 Necropsy cases
(6 positive, 17
negative)
(n.b., 1 positive
case because of
Neospora hughesi
not S. neurona)
 IFAT Se (100%) higher
than SAG2, 4/3 ELISA
Se (83%)
 SAG2, 4/3 ELISA Sp
(100%) higher than
IFAT Sp (82%)
IFAT advantages
include testing for
N. hughesi and
use as serum
stand-alone test.
(n.b., SAG2, 4/3
ELISA
serum:CSF ratio
had higher overall
accuracy.)
Johnson
et al. (2013)71
 IFAT (serum, CSF,
serum:CSF ratio)
 SAG2, 4/3 ELISA
(serum, CSF,
serum:CSF ratio)
 Necropsy cases
(11 positive,
28 negative)
 Clinical cases
(6 positive,
14 negative)
 SAG2, 4/3 ELISA
serum:CSF ratio was
most accurate (97%)
 IFAT CSF and
serum:CSF ratio also
had high accuracy (88%)
Serum testing
alone was least
accurate; more
accurate methods
should be used.
SAG2, 4/3 ELISA
serum:CSF ratio
was most
accurate.
ACVIM, American College of Veterinary Internal Medicine; EPM, equine protozoal myeloencephalitis; SIG, special interest group; WB,
Western blot; mWB, modified Western blot; IFAT, indirect fluorescent antibody test; SAG, surface antigen; ELISA, enzyme-linked
immunosorbent assay; Se, test sensitivity; Sp, test specificity; CSF, cerebrospinal fluid.
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(Table 3). An ELISA based on the major parasite sur-
face antigen NhSAG162 is available from Equine Diag-
nostic Solutions, LLC, whereas an IFAT using whole
N. hughesi tachyzoites is offered by the School of
Veterinary Medicine, University of California-Davis,
Veterinary Immunology Laboratory. Based on analysis
of 1006 random equine samples, the NhSAG1 ELISA
provides an estimated 94% sensitivity and 95% speci-
ficity for detecting antibodies against N. hughesi when
compared to Western blot results. The N. hughesi IFAT
sensitivity and specificity for detecting antibodies
against N. hughesi was reported to be 100% and
71.4%, respectively, at a cut-off of 1:320.100 These val-
ues were based on samples from 3 naturally infected, 7
experimentally infected, and 7 na€ıve horses. Of note,
neither the N. hughesi IFAT nor the NhSAG1 ELISA
have been fully validated for EPM diagnosis because of
an inadequate number of samples from EPM cases
caused by this parasite.
Recommendations for EPM Treatment and
Prevention
For treatment of EPM, it is recommended that 1 of
the FDA-approved anticoccidial drugs should be used
to control infection. The current FDA-approved drugs
are: a) Ponazuril (Marquis; Merial, Inc., Duluth,
Georgia, 30096, USA); b) Diclazuril (Protazil; Merck
Animal Health, Madison, NJ, 07940, USA); and c) Sul-
fadiazine/Pyrimethamine (eg, ReBalance; PRN Phar-
macal, Pensacola, Florida, 32514, USA). Additional
medical and supportive treatment should be provided
based on the severity of neurologic deficits and compli-
cations arising from them.
Basis for Recommendations
Folate-Inhibiting Drugs
A combination of sulfadiazine and pyrimethamine
(SDZ/PYR) was 1 of the initial treatment for EPM.
Sulfonamides and pyrimethamine act synergistically by
interfering with folic acid metabolism and biosynthesis
of purine and pyrimidine nucleotides necessary for the
parasite’s survival.
A dosage regimen of PYR, 1 mg/kg PO q24 h, and
SDZ, 20 mg/kg PO q24 h for up to 6 months was the
earliest treatment for EPM. As dietary folate can inter-
fere with the uptake of diaminopyrimidine drugs like
PYR,101 hay should not be fed for 2 hours before or
after treatment. PYR given PO to horses at 1 mg/kg/d
achieves a concentration of approximately 0.02 to
0.10 lg/mL in the CSF 4–6 h after administration.102
These experimental horses were allowed free access to
prairie hay, potentially reducing the bioavailability of
the drug.101 One of the PK characteristics is that
steady-state CSF concentrations of PYR can be
obtained after 4–6 hours after a single PO adminis-
tered dose at 1 mg/kg/d. Further, short half-lives of
these compounds suggest that there will be large fluc-
tuations between peak and trough concentrations in
the CSF after single daily administration. Additionally,
as PYR is concentrated in CNS tissue relative to
plasma,103 the concentration at the desired site of
action might be >0.1 lg/mL. Mean peak CSF concen-
trations of sulfonamide after single or multiple dosing
(22–44 mg/kg) have been reported to be approximately
2–8 lg/mL.104 These drugs are available as an FDA-
approved product (ReBalance; PRN Pharmacal).
Treatment efficacy determined by clinical improvement
(2 or more improvement grades in the overall neuro-
logic dysfunction) or reversion to a CSF negative sta-
tus for S. neurona by immunoblot after 90 days of
treatment showed success in 60–70% of treated
horses.105
The toxic effects of these drugs relate to the inhibi-
tion of folate synthesis and include bone marrow sup-
pression, anorexia, urticaria, and self-limiting
diarrhea.102,106 Typically, there is progressive mild ane-
mia (PCV in the low 20s) over a 6-month treatment
period; neutropenia and thrombocytopenia can be seen
in some cases as well. Pyrimethamine is teratogenic,
causing abortions in rats and congenital defects in
Table 3. Commercially available immunologic tests for antibodies against Neospora hughesi.
Test Laboratory Interpretation Reported performance
IFAT100 UC Davis  Serum positive at ≥1:320;
negative at <1:40
 CSF positive at ≥1:5
 Serum Se 100%, Sp 100%
at cutoff of 1:640
 Serum Se 100%, Sp 71%
at cutoff of 1:320
 Se and Sp estimates calculated
using samples from experimentally
infected horses, not EPM cases
ELISA62 EDS  Serum positive at ≥1:500
 CSF positive at ≥1:5
 Serum:CSF titer ratio
provides most accurate
EPM diagnosis
 Serum Se 94%, Sp 95% compared
to WB detection antibodies
(not EPM cases)
IFAT, indirect fluorescent antibody test; ELISA, enzyme-linked immunosorbent assay; UC Davis, University of California at Davis;
EDS, Equine Diagnostic Solutions (Lexington, KY); CSF, cerebrospinal fluid; EPM, equine protozoal myeloencephalitis; Se, sensitivity;
Sp, specificity; WB, Western blot.
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pups.107 In addition, mares treated with pyrimethamine
in late pregnancy had a fatal syndrome observed in the
foals.108 Of the 4 mares, 3 had been supplemented with
folic acid. In other species, folic acid supplementation
will not prevent PYR-induced toxicosis109 or can even
exacerbate it.107 Therefore, the use of folic acid in
EPM-affected horses treated with PYR cannot be justi-
fied.
Benzeneacetonitrile Drugs
Diclazuril and ponazuril, 2 members of the benze-
neacetonitrile group of compounds, have been
approved by the FDA for treatment of EPM (US
FDA, Protazil antiprotozoal oral pellets. 1.56% dicla-
zuril. Freedom of Information Summary; US FDA,
MarquisTM antiprotozoal oral paste. 15% w/w pon-
azuril. Freedom of Information Summary). With
demonstrated broad-spectrum anticoccidial activity in
many avian and mammalian species, these drugs are
related to the herbicide atrazine and are thought to tar-
get the parasite’s apicoplast organelle.110 The activity of
benzeneacetonitrile compounds against S. neurona and
N. caninum was initially shown in vitro.111–113 In horses,
pharmacokinetic studies have established that therapeu-
tic steady-state concentrations of both diclazuril and
ponazuril are achieved by day 7 using labeled doses.114–
116 Moreover, use of a loading dose of ponazuril at
15 mg/kg resulted in steady-state concentrations in
blood and CSF by day 2.117 Furthermore, the concur-
rent administration of vegetable oil (1/2 cup) has shown
to increase the bioavailability of the FDA-approved
ponazuril product up to 15% (M. Furr, unpublished
observations). A loading dose for the FDA-approved
diclazuril product is not required and use of vegetable
oil does not increase its bioavailability (Hunyadi,
unpublished observations). The FDA-approved benze-
neacetonitrile compounds exhibited efficacy ranging
from 62 to 67% based on a neurologic examination
improvement of 1 grade or becoming negative to anti-
bodies against S. neurona in serum and CSF.118
Because ponazuril and diclazuril are highly selective
against apicomplexan parasites, little to no toxicity is
to be expected at therapeutic doses.119
Duration of treatment will mainly depend on
response to antiprotozoal administration. While the
FDA-approved products are labeled for a treatment
course of 28 days, the majority of horses with EPM are
treated for a longer period of time, generally 6–8 weeks
or longer if clinical improvement is still apparent under
treatment. Discontinuation of antiprotozoal treatment
should be based on neurologic improvement. At this
time, antibody retesting in blood, CSF, or both is not
recommended to determine discontinuation of antipro-
tozoal drug administration.
Supportive Medical Treatment
Nonsteroidal anti-inflammatory drugs such as flunixin
meglumine are frequently given to moderately or
severely affected horses during the first 3–7 days of
antiprotozoal treatment and in an attempt to prevent
worsening of neurologic deficits during the early
antiprotozoal treatment. In the case of horses which are
in danger of falling down or exhibit signs of brain
involvement, the additional use of a short course of cor-
ticosteroids (0.1 mg/kg of dexamethasone once or twice
daily) and dimethyl sulfoxide (1 g/kg as a 10% solution
IV or by nasogastric tube once or twice daily) may con-
trol the inflammatory response and associated clinical
signs. Because the damaged CNS is susceptible to
oxidant injury, vitamin E (eg, 20 IU/kg daily per os) is
often used as an adjunct antioxidant treatment; it
remains to be determined experimentally whether this
practice is beneficial.
Biologic Response Modifiers
Based on the assumption that horses that develop
EPM may be immune compromised, immunomodula-
tors have anecdotally been included by some in treat-
ment of the disease. The drugs used include levamisole
(1 mg/kg PO q12h for the first 2 weeks of antiprotozoal
treatment and for the first week of each month there-
after), killed Propionibacterium acnes (EqstimTM; Neo-
gen, Lansing, MI), mycobacterial wall extract
(Equimune IV; Bioniche Animal Health Vetoquinol,
Belville, ON, Canada), inactivated parapox ovis virus
(Zylexis, Zoetis, Florham Park, NJ), and transfer factor
(4Life Transfer Factor, 4LifeResearch, Sandy, UT).
Because no studies have been conducted to evaluate
their efficacy in EPM horses, no recommendations can
be made.
Prevention of EPM
Preventative approaches to EPM can be achieved by
decreasing stress along with reducing exposure to scat
from opossums. Practical approaches such not feeding
off the ground, providing separate sources of fresh
water for horses and preventing wildlife access to horse
pastures, paddocks, and stalls may also help reduce the
incidence of protozoal infections in horses.
Intermittent use of coccidiostatic and coccidiocidal
drugs is another approach used to prevent EPM. Two
prophylactic studies have looked at the use of ponazuril
after an experimental challenge.120,121 Treatment at
either 2.5 or 5.0 mg/kg PO q24h of ponazuril was
administered beginning 7 days before experimental chal-
lenge and continued for 28 days.120 In that study,
administration of ponazuril reduced clinical signs and
delayed seroconversion. Intermittent ponazuril paste
administration at 20 mg/kg PO every 7 days was associ-
ated with a significantly decreased intrathecal anti-
S. neurona antibody response in horses experimentally
inoculated with S. neurona sporocysts.121 Collectively,
these 2 studies showed that daily or intermittent treat-
ment with ponazuril minimized but did not eliminate
infection in horses experimentally infected with S. neu-
rona. Recently, pharmacokinetics of daily low-dose
diclazuril (0.5 mg/kg PO q24h) given to adult healthy
horses were investigated.116 Diclazuril pellets, given at a
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low-dose, attained plasma and CSF concentrations
known to inhibit S. neurona and N. caninum in cell cul-
ture. The daily administration of a low-dose diclazuril
pellet topdressing to healthy foals from a farm with a
high exposure rate to S. neurona significantly reduced
the monthly seroprevalence to S. neurona when com-
pared to untreated foals.122 The authors of that study
suggested that the reported difference in temporal sero-
prevalence between treated and untreated foals was
likely because of the successful reduction of S. neurona
infection in foals receiving a daily low-dose diclazuril.
This preventive strategy has the potential to be used in
high-risk horses in an attempt to reduce the incidence
of EPM, although, future longitudinal studies will be
required before establishing a standard protocol.
Future directions
While considerable progress has been made as the
original EPM consensus statement in 2002, many ques-
tions remain unanswered. The highest priority areas
identified by the EPM organizing committee include:
(a) identifying whether S. neurona can establish a per-
sistent but inapparent infection in the horse, (b) eluci-
dating the nature of the immune response in
protection and disease, (c) determining how S. neurona
causes disease and whether organisms need to be pre-
sent to cause pathologic changes and clinical signs, (d)
elucidating whether S. neurona parasite genotype influ-
ences infection and severity of signs, (e) identifying
whether co-infection with other pathogens can be a
contributing factor in EPM cases, (f) expanding the
fundamental knowledge of N. hughesi as a cause of
EPM, including identifying the definitive host, deter-
mining all modes of transmission and investigating the
host-pathogen relationship, including the protective
immune response. The Committee urges support for
the aforementioned projects as the knowledge gained
from these studies will lead to earlier and more accu-
rate diagnosis, preventive approaches and more effica-
cious treatments.
Summary
Based on the currently published information, it is
recommended that horses with neurologic signs consis-
tent with EPM, because of S. neurona or N. hughesi,
have a thorough neurologic examination performed.
With this information, neurologic deficits can be identi-
fied and the lesion(s) localized. Differentials can be
developed and appropriate diagnostic testing can be
performed to rule in EPM and rule out other diseases.
Current recommendations are for serum and CSF test-
ing for S. neurona, N. hughesi, or both to identify
whether intrathecal antibody production is present.
Treatment recommendations for EPM include an FDA-
approved treatment, as well as supportive care. Dura-
tion of treatment is based on resolution of clinical signs.
Horses that develop recurrent signs should be reas-
sessed. As more knowledge is elucidated on the viru-
lence of S. neurona and N. hughesi and the immune
phenotype is elicited, more accurate diagnose, more effi-
cacious treatments, and better preventative approaches
will be identified.
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